TMDI - Titan Medical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.1700
-0.0500 (-2.25%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.2200
Open2.2400
Bid1.7000 x 2200
Ask2.6400 x 1800
Day's Range2.1500 - 2.2900
52 Week Range1.0500 - 4.6500
Volume231,712
Avg. Volume139,690
Market Cap66.901M
Beta (3Y Monthly)4.77
PE Ratio (TTM)N/A
EPS (TTM)-2.4870
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire

    Titan Medical Announces Successful Completion of Survival Phase of GLP Chronic Procedures with its Single-Port Robotic Surgical System

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces the successful completion of the chronic procedures performed under Good Laboratory Practice (“GLP”) principles using its single-port robotic surgery system, noting that all animals survived through the follow-up period. Ricardo Estape, M.D., a robotic gynecologic oncology surgeon specializing in robotic single incision surgeries from South Miami Gynecology Oncology Group, led the completion of the GLP studies. The Company now intends to complete the full GLP studies report and required Summative Human Factors studies, followed by the full Human Factors Evaluation (“HFE”) report to facilitate filing of the Investigational Device Exemption (“IDE”) submission by the end of September.

  • Business Wire

    Titan Medical Reports Second Quarter 2019 Financial Results

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or “the Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the three and six months ended June 30, 2019. All financial results are prepared in accordance with International Financial Reporting Standards (“IFRS”) and are reported in U.S. dollars, unless otherwise stated. David McNally, President and CEO of Titan Medical, said, “We continued to make steady progress during the second quarter of 2019 and in recent weeks, and moved closer to critical milestones associated with anticipated regulatory filings for our single-port robotic surgical system.

  • Zacks Small Cap Research

    TMDI: Titan Medical: Revolutionizing Minimally Invasive Surgery with Robotics!

    Titan Medical Inc. (TMD.TO) (TMDI) based in Toronto, Canada designs and develops computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). In the last decade, Titan has been focused on developing a single-port system for abdominal surgery which promises ease of use, design characteristics for superior clinical performance, operating room efficiency and cost benefit to hospitals. Stability and consistency of outcomes are of prime importance in interventional procedures since anatomical structures are complex and can be punctured easily.

  • Business Wire

    Titan Medical Completes Preclinical Good Laboratory Practice Procedures With Its Single-Port Robotic Surgical System

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that all procedures under Good Laboratory Practice (“GLP”) principles associated with the acute and chronic animal studies and human cadaver studies using its single-port robotic surgery system have been completed. The Company intends to announce the results of required follow-up to the chronic procedures by the end of August. “We are pleased to have completed all of the planned GLP procedures necessary for our Investigational Device Exemption (“IDE”) application to the U.S. Food and Drug Administration (“FDA”),” said David McNally, Titan’s chief executive officer.

  • Business Wire

    Titan Medical Names Surgical Robotics Sales Veteran Chad A. Zaring as its Chief Commercial Officer

    (July 8, 2019) – Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that Chad A. Zaring has joined the Company as chief commercial officer, a new position. Mr. Zaring has deep experience developing and executing commercial strategies and driving sales for leading surgical robotics companies and will be responsible for the launch of Titan’s single-port robotic surgery system following receipt of regulatory clearances.

  • Business Wire

    Titan Medical to Present and Exhibit at the Society of Robotic Surgery 2019 Annual Meeting

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that David McNally, President and CEO of Titan Medical, will present in the plenary session titled “Innovations in Robotic Technologies, What The Future Holds In Store” on Thursday, June 20 at the Society of Robotic Surgery 2019 Annual Meeting in Orlando. This industry-focused plenary session will feature executives from companies recognized for current and promising technology platforms in robotic surgery.

  • Titan Medical (TMDI) Shows Promise on Strategic Developments
    Zacks

    Titan Medical (TMDI) Shows Promise on Strategic Developments

    Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.

  • Business Wire

    Titan Medical Inc. Announces Voting Results from Its Annual and Special Meeting of Shareholders

    Titan Medical Inc. , a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery, reported shareholder vote results from the Company’s Annual and Special Meeting held on Wednesday, May 29, 2019.

  • Business Wire

    Titan Medical Annual and Special Meeting Scheduled for Wednesday, May 29, 2019

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces that its 2019 Annual and Special Meeting is scheduled for Wednesday, May 29, 2019 at 12:00 p.m. (Eastern), to be held at the Toronto Hilton Hotel, 145 Richmond Street West, Simcoe Room, Main Lobby. As the Exercise Price Amendment constitutes a “related party transaction” as such term is defined in Multilateral Instrument 61-101.

  • Business Wire

    Titan Medical Reports First Quarter 2019 Financial Results

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or “the Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the three months ended March 31, 2019. All financial results are prepared in accordance with International Financial Reporting Standards (“IFRS”) and are reported in U.S. dollars, unless otherwise stated. David McNally, President and CEO of Titan Medical, said, “We continued to make steady progress during the first quarter and recent weeks, moving closer to pivotal milestones in the development of our single-port robotic surgical system.

  • Business Wire

    Titan Medical Names Prominent Medical Technology Executive Charles Federico as Chairman of the Board

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces the appointment of Charles W. Federico, age 70, as Chairman of the Company’s Board of Directors, effective immediately. Mr. Federico is assuming the Board seat held by Bruce Wolff, M.D. who has resigned from the Board and is being retained as a Senior Advisor to the Company.

  • Business Wire

    Titan Medical Announces Hardware Design Freeze for its Single-port Robotic Surgery System

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces it has achieved hardware design freeze for its single-port robotic surgery system. Hardware design freeze is an essential milestone in the system design process as it allows Titan to complete various design verification and validation activities such as preclinical studies conducted under Good Laboratory Practices (“GLP”) and Summative Human Factors studies, in preparation for submitting an Investigational Device Exemption (“IDE”) to the U.S. Food and Drug Administration (“FDA”) for human confirmatory studies.

  • Business Wire

    Titan Medical to Present at the Bloom Burton & Co. Healthcare Investor Conference

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30 at 1:30 p.m. Eastern time. The conference will be held April 30-May 1 at the Metro Toronto Convention Centre, in Toronto, Canada. Mr. McNally’s presentation will be webcast live and available for replay in the Investors section of Titan Medical’s website at titanmedicalinc.com/investors.

  • Business Wire

    Titan Medical and Teleflex Incorporated Announce Collaboration for Development of Robotic Ligation Technology

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”) and Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, announce a collaboration under which Teleflex’s market-leading polymer ligation technology will be integrated into Titan’s development-stage, single-port robotic surgery system. Teleflex’s Weck® Hem-o-lok® polymer ligation system is a proven ligation technology for vessel sealing with enhanced clip security features that surgeons have used in millions of patients worldwide.

  • Business Wire

    Titan Medical to Webcast Business Update Conference Call on March 28, 2019

    Titan Medical Inc. , a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery , announces that management will webcast a conference call on Thursday, March 28 at 4:30 p.m.

  • Business Wire

    Titan Medical Closes Public Offering

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce the closing of its previously announced public offering (the “Offering”) pursuant to an agency agreement dated March 18, 2019 between the Company and Bloom Burton Securities Inc. (the “Agent”). The Company closed the Offering on March 21, 2019 and issued 7,352,941 units (the “Units”) for gross proceeds of approximately US $25,000,000. Each Unit was issued at a price of US $3.40 per Unit (the “Offering Price”) and is comprised of one common share of the Company (a “Common Share”) and one warrant entitling the holder to purchase one Common Share at a price of US $4.00 until expiry on March 20, 2024.

  • Business Wire

    Titan Medical Announces Filing of Final Prospectus

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce that yesterday it filed and was receipted for a final short form prospectus (the “Final Prospectus”) in connection with the previously announced marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offering, Titan will issue Units at a price of US $3.40 per Unit for gross proceeds of a minimum of US $20,000,000 and a maximum of US $25,000,000. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).

  • Business Wire

    Titan Medical Announces Pricing of Overnight Marketed Offering

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has priced its previously announced overnight marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offering, Titan will issue Units at a price of US $3.40 per Unit for total gross proceeds of a minimum of US$20,000,000 and a maximum of US$25,000,000. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).

  • Business Wire

    Titan Medical Expands Global Intellectual Property Portfolio to 30 Patents Issued and 75 Pending with Receipt of First Patent in China

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that its global intellectual property portfolio has increased to 30 issued patents and 75 pending applications through the recent granting and filing of patent applications directed at aspects of its innovative robotic surgery program. The recently granted Chinese patent describes the smooth and continuously curved articulation of a robotic instrument to position and orient an end-effector in multiple degrees of freedom.

  • Business Wire

    Titan Medical to Participate at Upcoming Investment Conferences

    Titan Medical Inc. , a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery , today announced that Company management will be participating in two upcoming investor conferences.

  • Business Wire

    Titan Medical Reports 2018 Financial Results

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the year ended December 31, 2018. David McNally, President and CEO, said, “2018 was an exceptionally busy and productive year for Titan Medical as we achieved all milestones related to the development of our SPORT single-port robotic surgery system. “During the fourth quarter we completed the system engineering confidence build for our next-generation SPORT Surgical System, including a new camera system and design enhancements to the surgeon workstation and the patient cart, the two primary components of the system.

  • Business Wire

    Peer-Reviewed Paper Featuring Titan Medical’s Single-Port Robotic Surgical Platform in General Surgery Published in Surgical Endoscopy

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that a peer-reviewed multi-faculty paper featuring Titan’s single-port platform has been published in the January 2019 issue of Surgical Endoscopy. The paper highlights the feasibility, safety and ease of use of Titan’s single-port robotic technology for general surgery procedures and is available here.

  • Business Wire

    Titan Medical Completes Build of Its Next-Generation Single-Port Robotic Surgical System

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has completed the system engineering confidence build for all components of its single-port robotic surgery system. This accomplishment highlights the completion of a new camera system along with the design enhancements of both the surgeon workstation and the patient cart, the two primary components of the system. The engineering confidence build reflects all significant improvements inspired by the Company’s preclinical experience.

  • Business Wire

    Titan Medical Affirms Timeline for U.S. and EU Regulatory Submissions by Year-End 2019 for Its Sport Surgical System

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), affirms its regulatory filing timeline with a 510(k) submission expected by the end of 2019 as a result of discussions with the U.S. Food and Drug Administration (“FDA”). The Company plans to complete the required human confirmatory studies under an Investigational Device Exemption (“IDE”) during the second half of 2019 in support of its 510(k) filing. Additionally, the Company confirms that it also expects to file for the CE mark by year-end 2019.